Special Issue

Recent Scientific Development of Poliovirus Vaccines

Message from the Guest Editor

In 1988, the World Health Assembly established the Global Polio Eradication Initiative, an international effort to terminate all transmissions of wild poliovirus by 2000. Eradication requires (1) effective means to prevent poliovirus infections and/or transmissions and (2) effective surveillance programs to identify poliovirus infections and evaluate the effectiveness of interventions in individuals and/or in unidentified persons within populations. Many stakeholders have been involved in developing and improving the two main types of vaccines in current use, inactivated (IPV) and live attenuated (OPV) vaccines. However, the ideal polio vaccine, "effective in any outbreak scenario, protect[ing] all vaccinees with one dose, spread[ing] to and protect the unvaccinated population, and have[ing] no detrimental effect" is yet to be developed. This Special Issue of *Vaccines* focuses on recent scientific advancements achieved from the development and field testing of improved, more genetically stable, oral polio vaccines as well as from current research on alternative vaccines and vaccination strategies.

Guest Editor

Prof. Dr. Lester M. Shulman

1. Retired, Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
2. Laboratory of Environmental Virology, Retired, Central Virology Laboratory, Public Health Services Israel Ministry of Health Sheba Medical Center, Tel Hashomer 52621, Israel

Deadline for manuscript submissions

31 January 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/197335

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI